Bristol-Myers secures positive EU opinion for Yervoy
This article was originally published in Scrip
Executive Summary
Following on from the FDA's broad label approval for Yervoy (ipilimumab) in March (scripintelligence.com, 28 March 2011) to treat first-line metastatic melanoma, experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) are also recommending European Union approval for the treatment of patients with previously-treated unresectable or metastatic melanoma.